Dospelin

There is no image.

Donepezil

Method of action: Anticholinesterase, Lipid Modifying Agents, M-N-Cholinomimetic, Psychoanaleptics

Treatment option: Dementia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dospelin

Property	Description
Active ingredient	Donepezil hydrochloride
Form	Oral tablets (film-coated)
Pharmacological class	Acetylcholinesterase Inhibitor (AChEI)
Common use	Support for cognitive function
Origin	Synthetic compound

Defining Dospelin: Identity and Pharmacological Class

Dospelin is a synthetic, prescription-only medicine whose core active component is the international non-proprietary name (INN) substance Donepezil hydrochloride. It is formally classified as a cholinesterase inhibitor, specifically an Acetylcholinesterase Inhibitor (AChEI). This classification identifies Dospelin as a centrally acting pharmacological agent designed to influence chemical processes within the brain. Donepezil maintains a recognized role within this therapeutic class, and Dospelin is typically prescribed for adult patient populations facing cognitive challenges.

Composition, Origin, and Pharmaceutical Form

The composition of Dospelin is based on the single active ingredient, Donepezil hydrochloride, which is administered primarily in the form of oral, film-coated tablets. Being a single-entity product, its therapeutic activity is attributed solely to the Donepezil molecule, which is manufactured as a synthetic compound. It is formulated with standard solid pharmaceutical excipients necessary for the tableting process. The oral route of administration dictates that the medication is absorbed systemically through the digestive tract to exert its central effects.

The General Purpose of Donepezil

The overall purpose of Donepezil is to support and enhance cognitive function by regulating key chemical signals in the brain, which are often reduced in certain neurocognitive conditions. Its action involves the reversible inhibition of acetylcholinesterase, the enzyme that normally breaks down the critical neurotransmitter acetylcholine. By temporarily slowing this natural breakdown, Donepezil helps sustain higher levels of acetylcholine at the nerve connections, a mechanism that supports improved communication between brain cells related to memory and attention, a benefit clinically recognized for its intended use scenario.

What side effects are possible with Dospelin?

The safety profile for Dospelin (Donepezil hydrochloride) details the officially documented adverse reactions and safety characteristics, which are classified by frequency and affected body system as per government regulatory documents.

Classification of Officially Documented Adverse Reactions

Adverse reactions are grouped into System-Organ Classes (SOCs) and assigned a frequency classification. Very Common reactions (ge 1/10) include diarrhea and headache. Common reactions (ge 1/100 to <1/10) involve the Nervous System (e.g., dizziness, insomnia, syncope), Gastrointestinal Disorders (e.g., nausea, vomiting, abdominal pain), and Psychiatric Disorders (e.g., hallucinations, agitation).

Uncommon reactions (ge 1/1,000 to <1/100) include seizures, bradycardia (slow heart rate), gastrointestinal bleeding, and peptic ulcers. Rare reactions (ge 1/10,000 to <1/1,000) documented in the label include hepatitis or liver dysfunction, and heart conduction issues like sinoatrial block.

Serious Adverse Reactions and Safety Notes

The label highlights serious adverse reactions that are clinically significant, such as significant gastrointestinal bleeding, seizures, severe heart conduction blocks, and signs of liver dysfunction. A Very Rare adverse event (<1/10,000) noted is Neuroleptic Malignant Syndrome (NMS).

Safety constraints and time-related patterns are also documented. Gastrointestinal adverse effects are cited as being more frequent at the initiation of treatment and during dose escalation. Furthermore, use is contraindicated in individuals with known hypersensitivity to the drug and in those with severe hepatic impairment. Caution is also advised for patients with a history of severe asthma or other obstructive pulmonary diseases.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents emphasize that an overdose of Dospelin is a serious medical emergency requiring immediate attention due to the risk of severe complications. Accidental ingestion, particularly by children, is associated with potentially life-threatening risks.

Documented Overdose Symptoms

The primary concern in an overdose is the development of a cholinergic crisis. The documented signs and symptoms, derived from official labeling, may include:

Cardiovascular: Significantly slowed heart rate (bradycardia) and low blood pressure (hypotension).
Gastrointestinal/Secretions: Severe nausea, severe vomiting, and excessive salivation and sweating.
Neurological: Muscle weakness, convulsions (seizures), and troubled breathing.

Emergency Action Required

Immediate medical help must be sought at once if an overdose is suspected, even if symptoms have not yet appeared. All official documents advise the following procedural actions:

Contact Emergency Services: Immediately call a healthcare professional, hospital emergency department, or regional Poison Control Centre.
Required Treatment: Medical management in a clinical setting is necessary. This involves the administration of a tertiary anticholinergic agent, such as atropine, to counteract severe muscarinic effects, particularly bradycardia and other life-threatening cardiovascular symptoms.

The potential for serious effects on the heart and breathing means an overdose should be treated with the utmost urgency.

Therapeutic Uses of Dospelin

What Dospelin Treats: Main Uses and Benefits

Dospelin is a prescription medication used to provide symptomatic support for dementia in adult patient populations. Its main therapeutic application is supportive management of cognitive and functional symptoms associated with Alzheimer's disease (AD), for which its use is relevant across mild, moderate, and severe stages.

“The application of Dospelin is relevant in conditions where core mental functions and day-to-day abilities are progressively affected.”

The medication plays a role in managing symptoms that create noticeable interference with daily stability, offering supportive relief when symptoms intensify or interfere with routine activities. It is commonly used to help manage core cognitive deficits, including memory, confusion, and difficulties with attention. It also contributes to the management of associated behavioral and mood disturbances like agitation or apathy. Applied as a long-term treatment, this support assists with maintaining functional stability and helps ease the overall symptom load for the patient and their caregivers.

Quick Fact: Relief for Cognitive Deficits Dospelin assists in maintaining functional stability related to attention and memory, which helps patients cope more steadily with symptom fluctuations in chronic conditions.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Dospelin use is restricted to the adult patient population with established safety and efficacy data, including older adults. The medicine is contraindicated for patients with a known hypersensitivity to the active substance, donepezil hydrochloride, or to related substances known as piperidine derivatives. Use is not recommended in children and adolescents below the age of 18 years, as regulatory authorities have not established safety or effectiveness in the pediatric population.

Use also requires caution in specific patient groups due to physiological considerations. This includes individuals with pre-existing cardiac conduction abnormalities, such as conditions that may cause bradycardia or heart block, and patients with a history of seizures. Furthermore, regulators advise care for patients with a history of asthma or obstructive pulmonary disease, and those at increased risk for developing peptic ulcers or gastrointestinal bleeding.

Regarding organ function, Dospelin is not recommended for patients with severe hepatic impairment due to insufficient data. However, a similar dosing schedule is permitted for patients with renal impairment. For women, use during pregnancy is not recommended unless clearly necessary, and women who are nursing should not breastfeed as its excretion into human milk is unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents describe interactions for Dospelin (Donepezil hydrochloride) based on two main pharmacological systems: pharmacokinetic clearance and pharmacodynamic effect.

Interaction Type	Interacting Categories/Substances (Examples)	Regulatory Constraint/Outcome
Pharmacodynamic (Synergistic/Antagonistic)	Anticholinergic Medications (e.g., Antihistamines), Cholinomimetics / Other Cholinesterase Inhibitors	Anticholinergics may interfere with Dospelin’s activity; other cholinesterase inhibitors may cause synergistic, exaggerated cholinergic effects and should be avoided.
Pharmacodynamic (Risk Augmentation)	NSAIDs, Beta-Blockers, QTc-Prolonging Agents	Increased risk of gastrointestinal bleeding with NSAIDs. Potential for additive bradycardia with beta-blockers. Caution is advised with QTc-prolonging agents.
Pharmacokinetic (Altered Exposure)	CYP3A4 Inhibitors (e.g., Ketoconazole), CYP2D6 Inhibitors (e.g., Quinidine)	Co-administration increases Dospelin plasma concentrations by reducing clearance.
Pharmacokinetic (Altered Exposure)	CYP Inducers (e.g., Rifampicin, Carbamazepine)	Co-administration may reduce Dospelin plasma concentrations.

During general anesthesia, Dospelin may exaggerate succinylcholine-type muscle relaxation. In patients with mild to moderate hepatic impairment, official labeling notes a potential for increased Donepezil exposure, while clearance is not affected in patients with renal impairment. Alcohol is noted as an enzyme inducer that may reduce Dospelin levels.

Mechanism of Action

Targeting Cholinergic Neurotransmission

Dospelin (donepezil) acts as a selective and reversible acetylcholinesterase inhibitor (AChEI). This enzyme, found primarily within the synaptic cleft, is responsible for the hydrolysis and inactivation of the neurotransmitter acetylcholine ( ACh). By binding to acetylcholinesterase, Dospelin prevents the rapid enzymatic breakdown of ACh. This inhibition prolongs the presence and concentration of ACh in central nervous system synapses, leading to enhanced cholinergic transmission.

Modulating Non-Cholinergic Pathways

Beyond enzyme inhibition, Dospelin engages secondary mechanisms. It has been shown to potentially upregulate nicotinic receptors in cortical neurons, potentially influencing downstream signaling that affects neuronal resilience. Furthermore, the drug may modulate neuroinflammatory responses, including the activation state of microglia and astrocytes, and affect certain voltage-activated ion currents. This broader mechanistic domain results in altered feedback regulation within targeted neural pathways and affects signaling pathways that modulate mediator release.

Dosage and Administration Information

How to use Dospelin — Official Administration Guidelines

Dospelin must be taken by oral administration only. The dosage regimen is initiated and adjusted by a specialist physician and should be strictly followed. The medication is typically taken once daily, in the evening, just prior to retiring.

Dosage and Timing

Administration Detail	Official Guideline
Starting Dose	5 mg once daily (usually in the evening)
Dose Escalation	The 5 mg dose must be maintained for at least one month before considering an increase to 10 mg.
Maximum Daily Dose	10 mg once daily. Doses exceeding 10 mg have not been studied in clinical trials.
Food/Fluid	May be taken with or without food. Swallow the tablet whole with a drink of water.
Sleep Disturbances	If sleep disturbances (e.g., insomnia, abnormal dreams) occur, the doctor may advise taking the dose in the morning instead of the evening.

Age and Health-Specific Rules

Elderly Patients: A similar dose schedule applies, but close supervision by a physician is necessary.
Paediatric Population (Under 18): Dospelin is not recommended for use in children or adolescents.
Renal Impairment: A similar dose schedule can be followed as clearance is generally unaffected by this condition.
Hepatic Impairment: For mild to moderate liver problems, dose adjustment should be performed gradually and according to individual tolerability due to possible increased drug exposure.

Procedural Note

If a dose is missed, do not take a double dose to compensate. Skip the missed dose and take the next tablet at the usual time the following day. If the treatment is missed for more than one week, contact a healthcare provider before resuming the medication.

Recent Clinical Evidence

Dospelin: Recent Clinical Evidence

The available research on Dospelin (Donepezil) is primarily focused on studying clinical patterns in patients who have been diagnosed with Alzheimer's disease (AD). The research used in research exploring how symptoms change over time uses standardized clinical assessments to monitor patterns in thinking, memory, and ability to perform daily activities.

Research for Mild to Moderate Alzheimer's Disease

The core research was studied for a number of short-term, randomized controlled trials (RCTs) to examine clinical patterns in patients with mild to moderate Alzheimer's disease. These trials monitored outcomes related to cognitive function, global clinical state, and outcomes reflecting daily functioning or activity level. Data show patterns related to measured differences in scores for cognitive function compared to the inactive control. However, many reviews emphasize that the magnitude of these measured changes was described as small by the researchers. Studies monitored quality of life, but findings were mixed and evidence is limited regarding a consistent influence.

Research for Moderate to Severe Alzheimer's Disease

Studies focusing on moderate to severe AD was evaluated in specific clinical trials designed to assess this population, often up to 24 weeks. The research examined outcomes using specialized scales relevant in trials assessing severe impairment, monitoring functional ability and global clinical state. The overall magnitude of the reported changes on cognitive and functional scales was observed in some studies to be small.

Long-Term Follow-up and Maintenance Studies

Research has examined whether the patterns observed in the initial short-term RCTs may continue over longer periods, such as one year or more. For the overall study populations, long-term effects are not fully established through controlled research. Limited information for long-term outcomes means that the durability of any observed changes and the overall influence on the long-term course of the condition remain uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dospelin (FAQ)

Q: What is Dospelin and what is it used for?

Dospelin is a medicine that contains the active substance Troleandomycin, which belongs to a group of medicines known as macrolide antibiotics. According to official product information, it is used to treat certain bacterial infections caused by germs that are sensitive to this antibiotic. The full list of specific conditions treated is always detailed in the regulatory documents.

Q: Can I use Dospelin to treat a cold or the flu?

Regulatory documents state that Dospelin is an antibiotic, meaning it is used to fight infections caused by bacteria. Colds and the flu are typically caused by viruses, and antibiotics are not effective against viral infections. Therefore, Dospelin is not indicated by the official labeling for treating viral illnesses like the common cold or influenza.

Q: What should I do if I miss a dose of Dospelin?

Official product information provides general guidance for managing a missed dose. Regulatory documents typically outline options, such as taking the dose if remembered soon, or skipping it if it is close to the next scheduled time. Specific directions should always be found within the product leaflet or discussed with a healthcare provider. Double dosing to make up for a missed one is advised against in the official documentation.

Q: How should Dospelin be stored?

According to the official product information, Dospelin should be stored at a temperature below 30°C. It is crucial to keep the medicine out of the sight and reach of children and pets for safety. Additionally, the product should not be used after the expiry date printed on the packaging.

Q: What is the active ingredient in Dospelin?

Studies and official information indicate that the active ingredient in Dospelin is Troleandomycin. This substance is primarily responsible for the medicine's effect of fighting sensitive bacterial infections. The product also contains various inactive ingredients, which are detailed in the official regulatory documentation.

How should Dospelin be stored and disposed of?

How to Store and Dispose of Dospelin?

The storage and disposal instructions for Dospelin (donepezil hydrochloride) are defined by official government regulatory requirements to ensure product integrity and public safety.

Storage Requirements

Dospelin tablets must be kept at Controlled Room Temperature, which is generally defined as 15 C to 30 C. The product must be stored in its original, tightly closed container and protected from excess heat and moisture; therefore, storage in a bathroom is discouraged. For safety, the medication must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Dospelin should be disposed of via an official drug take-back program. If this is not available, the medication must be mixed with an undesirable substance (such as coffee grounds or kitty litter), sealed in a bag, and placed in the household trash. The labeling specifies that Dospelin is not to be flushed down the toilet or poured into any wastewater system.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Czech Republic

Romania

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z